King's College London

Research portal

Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study

Research output: Contribution to journalArticlepeer-review

Heidi Walters, Maelys Touya, Soon Nan Wee, Michelle Ng, Simran Thadani, Subina Surendran, Miguel E Rentería, A. John Rush, Rashmi Patel, Joydeep Sarkar, Heather M. Fitzgerald, Xue Han

Bibliographical note

Funding Information: This study was funded by Otsuka Pharmaceutical Development & Commercialization, Inc. and Lundbeck LLC. Funding Information: HCW and XH are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. MT and HF were employees of Lundbeck LLC. at the time of the study. RP has received funding from the National Institute of Health Research (NIHR301690), the Medical Research Council (MR/S003118/1), the Academy of Medical Sciences (SGL015/1020), Holmusk, and Janssen. SW, MN, ST, SS, MR, RP, and JS report current or past employment of KKT Technology Pte. Ltd or its subsidiaries (Holmusk Technologies Inc. or Holmusk Europe Limited). Holmusk Technologies Inc. was paid for this research. Peer reviewers on this manuscript have no relevant financial or other relationships to disclose. Publisher Copyright: © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

Documents

King's Authors

Abstract

Objectives: This observational retrospective real-world study examined changes in healthcare resource utilization (HCRU) pre- and post-initiation of aripiprazole once-monthly (AOM 400) in patients with schizophrenia or bipolar I disorder. Methods: Electronic health record-derived, de-identified data from the NeuroBlu Database (2013–2020) were used to identify patients ≥18 years with schizophrenia (n = 222) or bipolar I disorder (n = 129) who were prescribed AOM 400, and had visit data within 3, 6, 9, or 12 months pre- and post-initial AOM 400 prescription. Rates of inpatient hospitalization, emergency department visits, inpatient readmissions, and average length of stay were examined and compared over 3, 6, 9, and 12 months pre-/post-AOM 400 using a McNemar test. Results: Statistically significant differences were seen in both schizophrenia and bipolar I disorder patient cohorts pre- and post-AOM 400 in inpatient hospitalization rates (p <.001 all time points, both cohorts) and 30-day readmission per patient rates (p <.001 all time points, both cohorts). Statistically significant improvement in mean length of stay was observed in both cohorts at all time points, except for at six months in patients with schizophrenia. Emergency department visit rates were significantly lower after AOM 400 initiation for both cohorts at all time points (p <.001). Conclusions: A reduction in the rate of hospitalizations, emergency department visits, 30-day readmissions, and average length-of-stay was observed for patients diagnosed with either schizophrenia or bipolar I disorder, which suggests a positive effect of AOM 400 treatment on HCRU outcomes and is supportive of earlier analyses from different data sources.

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454